Cannabis

CANNASWEEP

September 2024 OFW’s Cannabis Team regularly monitors cannabis news, legislation, regulation, and policy so our clients stay up-to-date on the latest developments impacting their business. If you have any questions or would like more information about any of the items below, please contact us. We also track cannabis-related legislation introduced in the U.S. Congress.  If you would […]

CANNASWEEP Read More »

CANNASWEEP

August 2024 OFW’s Cannabis Team regularly monitors cannabis news, legislation, regulation, and policy. Our monthly CannaSweep publication summarizes this coverage to keep our clients up-to-date on the latest developments impacting their business. Contact Ben Dash about our Congressional Bill Tracker for monthly tracking of cannabis-related legislation introduced in the U.S. Congress. Please contact us if you have

CANNASWEEP Read More »

FDA and FTC Issue Warning Letters to Companies Selling Copycat Delta-8 THC Food Products

On July 16, 2024, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued warning letters to six companies for illegally selling copycat food products containing delta-8 tetrahydrocannabinol (THC) and introducing them into the marketplace, violating the Federal Food, Drug, and Cosmetic (FD&C) Act. The FDA highlighted two primary concerns: the

FDA and FTC Issue Warning Letters to Companies Selling Copycat Delta-8 THC Food Products Read More »

Cannabis Administration and Opportunity Act (CAOA) Reintroduced Following Rescheduling Announcement

On May 1, 2024, Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR), and Senator Cory Booker (D-N.J.)  reintroduced the Cannabis Administration Opportunity Act (text available here). The reintroduction follows the news last week that the Drug Enforcement Administration (DEA) had begun the formal rulemaking process to move marijuana from Schedule I

Cannabis Administration and Opportunity Act (CAOA) Reintroduced Following Rescheduling Announcement Read More »

CANNASWEEP

WEEK OF APRIL 5, 2024 OFW’s Cannabis Team regularly monitors cannabis news, legislation, regulation, and policy so our clients stay up-to-date on the latest developments impacting their business. If you have any questions or would like more information about any of the items below, please contact us. We also track cannabis-related legislation introduced in the U.S. Congress. 

CANNASWEEP Read More »

CANNASWEEP 

WEEK OF March 8, 2024  OFW’s Cannabis Team regularly monitors cannabis news, legislation, regulation, and policy so our clients stay up-to-date on the latest developments impacting their business.  If you have any questions or would like more information about any of the items below, please contact us.  We also track cannabis-related legislation introduced in the U.S. Congress. 

CANNASWEEP  Read More »

CannaSweep’s Congressional Bill Tracker Can Enhance Your Cannabis Business

The cannabis industry is one of the most dynamic and complex sectors in the country, with varying degrees of legalization and regulation across different states and federal levels. Keeping track of federal cannabis-related bills and their status can be a daunting and time-consuming task. CannaSweep’s Congressional Bill Tracker is an outsourcing solution that industry members can

CannaSweep’s Congressional Bill Tracker Can Enhance Your Cannabis Business Read More »

CBD AND DELTA-8 THC – UPDATE ON FDA ENFORCEMENT

As part of its ongoing enforcement against unlawful cannabis-containing foods and dietary supplements, the U.S. Food and Drug Administration (FDA) has recently posted two new Warning Letters against cannabis marketers: Both Warning Letters cite the marketers for promoting and distributing human and animal foods and dietary supplements containing (or that purport to contain) the cannabinoids

CBD AND DELTA-8 THC – UPDATE ON FDA ENFORCEMENT Read More »

Comment Period on First Congressional Bipartisan and Bicameral Request for Information on Cannabidiol Closes

On August 18, 2023, comments were due to Congress on the bipartisan and bicameral request for information (RFI), which sought written stakeholder comments and analysis to “asses[s] the potential for a regulatory pathway for hemp-derived [cannabidiol (CBD)] products that prioritizes consumer safety and provides certainty to the U.S. market.”   By way of background on

Comment Period on First Congressional Bipartisan and Bicameral Request for Information on Cannabidiol Closes Read More »

FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs

On Friday, U.S. Food and Drug Administration (FDA) released its first draft guidance on the conduct of clinical trials for psychedelic drugs. The Draft Guidance for Industry, Psychedelic Drugs: Considerations for Clinical Investigations, if finalized, will guide researchers investigating psychedelics as potential treatments for medical conditions.  There has been significant media, marketing, and legislative interest

FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs Read More »

Hemp Now Included in Agricultural Technical Advisory Committee (ATAC)

The United States Department of Agriculture (USDA) will include ‘Hemp’ in the title of one of the six Agricultural Technical Advisory Committees (ATACs) – noting a significant evolution in both agriculture and cannabis policy. Specifically, ‘Hemp’ has now earned a place within the ATAC titled ‘Tobacco, Cotton, Peanuts, and Hemp.’ The ATACs were established under

Hemp Now Included in Agricultural Technical Advisory Committee (ATAC) Read More »